Anti-cancer drug T-DM1 benefits women with advanced breast cancer who have failed several previous treatments: results from TH3RESA trial
First results from a phase III clinical trial of the combination drug, T-DM1, show that it significantly improves the length of time before the disease worsens in women with advanced HER2 positive breast cancer whose cancer has recurred or progressed despite previous treatments, including trastuzumab and lapatinib... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 28, 2013 Category: Consumer Health News Tags: Clinical Trials / Drug Trials Source Type: news

Roche's Kadcyla helped people with advanced HER2-positive breast cancer live longer without their disease worsening in new phase III study
Roche today announced that Kadcyla (trastuzumab emtansine) significantly extended the time people with advanced HER2-positive breast cancer (metastatic and unresectable locally advanced/recurrent) lived without their disease worsening (progression-free survival [PFS], a co-primary endpoint) compared to people who received a treatment of their physician's choice in an open-label phase III study called TH3RESA. (Source: Roche Media News)
Source: Roche Media News - September 28, 2013 Category: Pharmaceuticals Source Type: news

Anti-cancer drug T-DM1 benefits women with advanced breast cancer who've failed previous treatments
(ECCO-the European CanCer Organisation) First results from a phase III clinical trial of the combination drug, T-DM1, show that it significantly improves the length of time before the disease worsens in women with advanced HER2 positive breast cancer whose cancer has recurred or progressed despite previous treatments, including trastuzumab and lapatinib. The research will be presented in a late-breaking presentation to the European Cancer Congress in Amsterdam. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 27, 2013 Category: Cancer & Oncology Source Type: news

Sharks' antibodies may yield new cancer drug
University of Aberdeen researchers have taken HER2 protein, which sits on the surface of tumours and fuels their growth, and injected it into sharks. (Source: the Mail online | Health)
Source: the Mail online | Health - September 26, 2013 Category: Consumer Health News Source Type: news

Breast cancer test may stop un-needed therapy
Conclusion It is fair to say that it is not clear what the effect on the overall percentage of patients having chemotherapy is at this moment in time. But better targeting of chemotherapy – giving it to those who are more likely to benefit from it – may also help women avoid unnecessary treatment and potential harm. The test may also help to alleviate some of the emotional and psychological strain experienced by patients who are currently placed in the “intermediate” risk category. Analysis by Bazian. Edited by NHS Choices. Follow Behind the Headlines on twitter. Links To The Headlines New br...
Source: NHS News Feed - September 26, 2013 Category: Consumer Health News Tags: Genetics/stem cells Cancer QA articles Source Type: news

New patient-focused five minute Herceptin® (trastuzumab) jab given green light by regulators & NHS England
Patients with a very aggressive form of breast cancer known as HER2-positive, could now benefit from a new faster, more efficient delivery method of Herceptin. The subcutaneous (SC) injection, given just beneath the skin, can be completed in 2-5 minutes, compared to the traditional, relatively time-consuming 30-90 minute intravenous (IV) infusion.[v] This speedier form of delivery of Herceptin is now authorised for use in the UK after a licence was granted by the European Medicines Agency (EMA). In addition, NHS England has agreed to fund its use on the NHS... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 25, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

First HER2 targeted Antibody Drug Conjugate Kadcyla, an Anti-Cancer Agent Approved for HER2-positive Inoperable or Recurrent Breast Cancer
Attached a press release by Chugai. (Source: Roche Investor Update)
Source: Roche Investor Update - September 20, 2013 Category: Pharmaceuticals Source Type: news

CHMP grants positive opinion for Roche's Kadcyla, the first antibody-drug conjugate for advanced HER2-positive breast cancer
Roche today announced that the European Union’s (EU) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Kadcyla (trastuzumab emtansine or T-DM1) as a single agent, for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. (Source: Roche Media News)
Source: Roche Media News - September 20, 2013 Category: Pharmaceuticals Source Type: news

Potential personalised therapy for a specific kind of pancreatic cancer
Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin. Pancreatic cancer is the fourth leading cause of cause of cancer death in Western societies, with a 5-year survival rate of less than 5%. It is a molecularly diverse disease, meaning that each tumour will respond only to specific treatments that target its unique molecular make-up... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 18, 2013 Category: Consumer Health News Tags: Pancreatic Cancer Source Type: news

Potential treatment for a specific kind of pancreatic cancer
(Garvan Institute of Medical Research) Researchers from Sydney's Garvan Institute of Medical Research have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2 percent of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 16, 2013 Category: Global & Universal Source Type: news

Antibody Array-ELISA Kits for Cancer Researchers
We continue to build our catalog of Antibody Arrays & ELISA Kitsfor Cancer Researchers. Our RayBio® C-Series Ctyokine Arraysenable you to analyze the expression of up to 120 Cytokines for aboutthe price of a single ELISA (585 USD). Figure 3. PTEN Downregulation in HER2-Overexpressing Cells Activates an IL6/NF-kB-Mediated Inflammatory Feedback Loop (A–E) MCF7-HER2+PTEN cells secreted 3- to 5-fold higher levels of IL6, IL8, and CCL5 compared to MCF7-HER2+ or MCF7-PTEN cells as determined by RayBio human cytokine antibody Array 5 (A). The intensity of each blot compared to control was determined by Kodak im...
Source: Neuromics - September 15, 2013 Category: Neuroscience Tags: C-Series Antibody Arrays cancer markers Cancer Research Cytokines ELISA Kits. VEGFs Interleukins Raybio Raybiotech Source Type: news

Short Course of Chemo Effective in Early-Stage HER2 Breast Cancer
Combining four cycles of docetaxel and cyclophosphamide with 1 year of trastuzumab may be a viable treatment option for women with HER2-amplified early-stage breast cancer regardless of their TOP2A status, according to the results of a phase II study. (Source: Cancer Network)
Source: Cancer Network - September 14, 2013 Category: Cancer & Oncology Source Type: news

FDA Advisory Committee recommends accelerated approval of Roche's Perjeta for neoadjuvant use in HER2-positive early stage breast cancer
Roche today announced that the United States (U.S.) Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 13 to 0, with one abstention, in favour of recommending accelerated approval of a Perjeta® (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk HER2-positive early stage breast cancer. The FDA will make a decision on whether or not to approve Perjeta for this use by 31 October, 2013. If approved, the Perjeta regimen will be the first neoadjuvant breast cancer treatment approved in the U.S. and the first treatment approved based on patholog...
Source: Roche Investor Update - September 13, 2013 Category: Pharmaceuticals Source Type: news

FDA Panel Sets Stage for 'Landmark Approval' of HER2 DrugFDA Panel Sets Stage for 'Landmark Approval' of HER2 Drug
Pertuzumab could be the first medicine approved for the neoadjuvant treatment of breast cancer. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 12, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Is HER2 Too Much Bother in Lung Cancer? Is HER2 Too Much Bother in Lung Cancer?
Dr. Jack West reports on a study assessing HER2/neu as a potential target in non-small cell lung cancer -- and finds cause for pause in the rush to identify more therapeutic targets. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 12, 2013 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

Breast Cancer: Preop Targeted Tx Effective
SAN FRANCISCO (MedPage Today) -- Dual HER2-targeted neoadjuvant therapy led to odds of pathologic complete response similar to those associated with trastuzumab and chemotherapy, a meta-analysis suggested. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 10, 2013 Category: Hematology Source Type: news

FDA Panel Votes On Perjeta For Pre-Surgical HER2 Breast Cancer Treatment
Art © Pam Stephan Imagine having a drug that is able to shrink a breast tumor so efficiently that your surgeon can no longer find it. Imagine benefiting from a drug that targets your cancer and is less toxic to your other tissues. Imagine finding the "Off" switch to an aggressive cancer and shutting it down - permanently. Breast cancer patients may soon have access to that drug - Perjeta (Pertuzumab) - for all stages...Read Full Post (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - September 10, 2013 Category: Cancer & Oncology Source Type: news

HER2-Positive Breast Cancer Patients Prefer Subcutaneous Trastuzumab
Results of the PrefHer study indicated that when given the option between subcutaneous trastuzumab and intravenous trastuzumab, significantly more patients with HER2-positive breast cancer preferred the subcutaneous administration. (Source: Cancer Network)
Source: Cancer Network - September 3, 2013 Category: Cancer & Oncology Source Type: news

Roche's new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer
Subcutaneous formulation is administered in two to five minutes, rather than 30 to 90 minutes with the standard intravenous form; Herceptin is used to treat more than 80,000 patients each year in Europe (Source: Roche Media News)
Source: Roche Media News - September 2, 2013 Category: Pharmaceuticals Source Type: news

Roche's new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission for the treatment of HER2-positive breast cancer, an aggressive sub-type of the disease. The approval is for both early and later stages of treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - September 2, 2013 Category: Pharmaceuticals Source Type: news

Roche’s injectable Herceptin formula endorsed by the EU
Roche has won EU approval for a new injectable formula of its breast cancer drug, Herceptin, to treat the HER2-positive type of the disease. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - September 2, 2013 Category: Pharmaceuticals Source Type: news

HER2/Neu Genetic Heterogeneity in HER2/Neu Breast CancerHER2/Neu Genetic Heterogeneity in HER2/Neu Breast Cancer
This study investigated the prevalence of HER2 genetic heterogeneity without, or with equivocal, HER2 amplification. What is its relationship to various clinicopathological prognostic factors? Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 30, 2013 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Highly specific new antibody introduced to boost HER2 type cancer research
A highly specific HER3 rabbit monoclonal antibody (mAb) developed by use-based Cell Signaling Technology could provide important new information for researchers studying HER2-mediated breast, lung and ovarian tumours. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 28, 2013 Category: Pharmaceuticals Source Type: news

GSK receives EMA approval for new Tyverb®
The European Medicines Agency (EMA) has granted an update to the marketing authorisation for Tyverb® (lapatinib) to be used in combination with Herceptin® (trastuzumab). This combination is indicated for adult patients with breast cancer whose tumours over express HER2 (ErbB2) with hormone receptor-negative (HR-) metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy. You must sign in to continue reading this article Hide related content:  Show related content read more (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 22, 2013 Category: Drugs & Pharmacology Authors: mz_loader Tags: *** Editor's Pick Oncology Latest News Source Type: news

GSK receives EMA approval for new Tyverb®
The European Medicines Agency (EMA) has granted an update to the marketing authorisation for Tyverb® (lapatinib) to be used in combination with Herceptin® (trastuzumab). This combination is indicated for adult patients with breast cancer whose tumours over express HER2 (ErbB2) with hormone receptor-negative (HR-) metastatic disease that has progressed on prior trastuzumab therapy(ies) in combination with chemotherapy. (Source: Pharmacy Europe)
Source: Pharmacy Europe - August 21, 2013 Category: Drugs & Pharmacology Source Type: news

Age Not Predictive of Recurrence in HER2 Breast Cancer
A retrospective analysis of the HERA trial indicated that young age was not associated with early recurrence in women with HER2-positive breast cancer, despite previous research suggesting that young age at diagnosis might be a risk factor for recurrence and death. (Source: Cancer Network)
Source: Cancer Network - August 19, 2013 Category: Cancer & Oncology Source Type: news

HER2 Signaling Activation in HER2-Negative Breast CancersHER2 Signaling Activation in HER2-Negative Breast Cancers
Using reverse-phase protein microarray, the authors were able to detect modified forms of HER2 in breast cancer tissue that, even in the absence of HER2 overexpression, could affect normal signaling. Expert Review of Proteomics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 15, 2013 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

GSK receives marketing authorisation from the European Commission for additional indication: Tyverb™ (lapatinib) in combination with trastuzumab for patients with HER2-positive, HR-negative metastatic breast cancer
GlaxoSmithKline announced today that the European Commission has granted an additional indication for Tyverb™ (lapatinib) to be used in combination with trastuzumab. (Source: GSK news)
Source: GSK news - August 14, 2013 Category: Pharmaceuticals Source Type: news

Aggressive "triple-negative" breast cancers may be sensitive to drugs that clog their waste disposal
In a new paper in Cancer Cell, a team led by Judy Lieberman, PhD, of Boston Children's Hospital's Program in Cellular and Molecular Medicine reports "triple-negative" breast cancers may be vulnerable to drugs that attack the proteasome. This cellular structure acts as the cell's waste disposal, breaking down damaged or unneeded proteins. These cancers, which lack the three major therapeutic markers for breast cancer - the estrogen, progesterone and HER2 receptors - are very aggressive and difficult to treat... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 14, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Drugs that clog 'waste disposal' may treat aggressive breast cancers
In a new paper in Cancer Cell, a team led by Judy Lieberman, PhD, of Boston Children's Hospital's Program in Cellular and Molecular Medicine reports "triple-negative" breast cancers may be vulnerable to drugs that attack the proteasome. This cellular structure acts as the cell's waste disposal, breaking down damaged or unneeded proteins. These cancers, which lack the three major therapeutic markers for breast cancer - the estrogen, progesterone and HER2 receptors - are very aggressive and difficult to treat... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 14, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Multipronged approach attacks breast cancer cells, blocking the growth of cancer-supporting blood vessels, stimulating antitumor immune response
A unique nanoscale drug that can carry a variety of weapons and sneak into cancer cells to break them down from the inside has a new component: a protein that stimulates the immune system to attack HER2-positive breast cancer cells. The research team developing the drug - led by scientists at the Nanomedicine Research Center, part of the Maxine Dunitz Neurosurgical Institute in the Department of Neurosurgery at Cedars-Sinai Medical Center - conducted the study in laboratory mice with implanted human breast cancer cells... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Neoadjuvant Trastuzumab Plus Chemo in Primary Breast CancerNeoadjuvant Trastuzumab Plus Chemo in Primary Breast Cancer
Does the pathological complete response rate to trastuzumab in HER2-positive breast cancer depend on the level of HER2 mRNA expression? Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 2, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Hitting HER2+ Breast Cancer With Both BarrelsHitting HER2+ Breast Cancer With Both Barrels
Dr. Lidia Schapira reports on a study showing an approach using targeted and hormonal therapies that can render chemotherapy unnecessary in a population of HER2+ breast cancer patients. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 25, 2013 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

A Triple Whammy for HER2+ Breast CancerA Triple Whammy for HER2+ Breast Cancer
Dr. Lidia Schapira reports on a study showing an approach using targeted and hormonal therapies that may render chemotherapy unnecessary in a population of HER2+ breast cancer patients. Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 25, 2013 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

Pertuzumab Granted Priority Review for Neoadjuvant HER2-Positive Breast Cancer
Last week, the FDA announced that it would grant priority review to pertuzumab (Perjeta), as a neoadjuvant treatment for women with HER2-positive early-stage breast cancer. (Source: Cancer Network)
Source: Cancer Network - July 9, 2013 Category: Cancer & Oncology Source Type: news

PHARE: One-Year Trastuzumab Remains Standard for HER2-Positive Breast Cancer
A 6-month regimen of treatment with trastuzumab for HER2-positive breast cancer failed to show noninferiority with the standard 12-month treatment regimen after 3.5 years of follow-up in the open-label, randomized, phase III PHARE trial. (Source: Cancer Network)
Source: Cancer Network - July 3, 2013 Category: Cancer & Oncology Source Type: news

FDA Grants Genentech's Perjeta Regimen Priority Review for Use Before Surgery in HER2-Positive Early Stage Breast Cancer
Application follows proposed new FDA pathway designed to help bring promising medicines to people with earlier stages of breast cancer faster (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 2, 2013 Category: Pharmaceuticals Authors: Pharma Manufacturing Source Type: news

FDA grants Roche's Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early-stage breast cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - July 2, 2013 Category: Pharmaceuticals Source Type: news

FDA grants Roche's Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early-stage breast cancer. (Source: Roche Media News)
Source: Roche Media News - July 2, 2013 Category: Pharmaceuticals Source Type: news

Low-Dose Chemo for Low Toxicity in Breast CancerLow-Dose Chemo for Low Toxicity in Breast Cancer
Dr. Laura Orlando describes impressive early results in treating advanced HER2-positive breast cancer with a combination of trastuzumab and low-dose chemotherapy. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2013 Category: Consumer Health News Tags: Hematology-Oncology Expert Interview Source Type: news

Anti-Cancer Agent Perjeta Approved for HER2-positive Inoperable or Recurrent Breast Cancer
Dear Investor, Please find attached a press release by Chugai. (Source: Roche Investor Update)
Source: Roche Investor Update - July 1, 2013 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche's Subcutaneous Herceptin for HER2 positive breast cancer
- New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients' time - Herceptin® is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year Roche (SIX: RO, ROG; OTCQX: RHHBY) is pleased to announce that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has today recommended EU approval of a subcutaneous formulation of Herceptin® (trastuzumab) for the treatment of patients with HER2-positive breast cancer. ...
Source: Roche Investor Update - June 28, 2013 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche's Subcutaneous Herceptin for HER2 positive breast cancer
- New injectable administration takes two to five minutes, rather than 30 to 90 minutes with the current intravenous form, potentially saving both healthcare resources and patients' time - Herceptin® is a personalised medicine used to treat more than 80,000 HER2-positive breast cancer patients in Europe each year (Source: Roche Media News)
Source: Roche Media News - June 28, 2013 Category: Pharmaceuticals Source Type: news

UK Lags Behind EU Counterparts In Uptake Of Oncology Biomarker Testing
Research reveals that the uptake of diagnostic testing amongst cancer patients in the UK trails behind that of other Western European markets. The data, which comes from Ipsos Healthcare's Global Oncology Monitor, shows that across three of the most highly-researched oncology biomarkers - HER2, KRAS and EGFR mutation - the proportion of relevant patients undergoing genetic testing in the UK was behind the EU4 average for the past few years. In fact, more often than not, the UK trailed each of the four individual markets... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 27, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

More Targets for Lung Cancer Therapy on the HorizonMore Targets for Lung Cancer Therapy on the Horizon
Dr. Maurie Markman reviews a recent article on HER2 mutations in lung cancer and considers whether HER2-targeting agents might be useful in these patients. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 20, 2013 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

BOLERO-3: Adding Everolimus Improves PFS in HER2+ Breast Cancer
The addition of everolimus (Novartis) to combination trastuzumab/vinorelbine leads to a significant improvement in progression-free survival compared with placebo in advanced and metastatic HER2-positive breast cancer. (Source: Cancer Network)
Source: Cancer Network - June 20, 2013 Category: Cancer & Oncology Source Type: news

Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
A high baseline level of soluble human epidermal growth factor receptor 2 (sHER2) was a prognostic indicator of shorter disease-free survival among patients with early-stage HER2-positive breast cancer, according to results from the North Central Cancer Treatment Group adjuvant trial N9831. (Source: Cancer Network)
Source: Cancer Network - June 20, 2013 Category: Cancer & Oncology Source Type: news

HER2/neu and Diagnosis
HER2, which is also called HER2/neu, and HER-2, is the acronym for human epidermal growth factor receptor 2. Knowing your HER2 status is an important part of your diagnosis. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 19, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Automated vs Manual FISH for Evaluation of HER2 StatusAutomated vs Manual FISH for Evaluation of HER2 Status
Does the automation of HER2 FISH improve the accuracy of HER2 gene testing in breast biopsy specimens? BMC Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2013 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Targeting HER2 in Esophageal CancerTargeting HER2 in Esophageal Cancer
Human epidermal growth factor antagonists are being tested in HER2-positive gastric and gastroesophageal junction tumors. Cancer Control: Journal of the Moffitt Cancer Center (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news